Skip to content

Study Details

Testing the Treatment of Donor Cell Transplants for Children and Young Adults with Severe Myeloid Leukemia

(IRB#: IRB_00152764)

This study is testing the treatment with Natural Killer cells from a donor to a patient, which may lower the chance that a blood disease severe myeloid leukemia will come back after a haploidentical (half-matched) transplant (moving cells from a donor to a patient). The study wants to see if the treatment will help people with severe myeloid leukemia. People in the study will receive Natural Killer cells from a central line placed in the body, most likely the chest. A central line is a tube that allows medications, medical tests, and transfusions to occur. Transfusion is a way to move blood from a donor to a patient. Being in the study requires attending in-person study visits at a clinic for about 2 years. Medical tests will be done to track the health of participants.


  • All genders
  • All Ages
  • Volunteers with special conditions
  •   In Person
  • Unpaid

Who can participate?

 Gender: All genders

  Age: All Ages

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Patients ages 4 months to 25 years old and donors ages 18 years and older
  • Patient diagnosis of severe myeloid leukemia
  • Patient recovery from a prior cycle of chemotherapy (a way to treat a disease such as cancer)
  • Patients major organs (lung, heart, kidneys) function
  • Donor matches specific criteria for the patient to receive the treatment

Exclusion Criteria

  • Patient has ongoing serious infections
  • Patient is pregnant
  • Patient has prior cell transplant
  • Patients with other specific genetic diseases
  • Donor unable to stop medication that may affect the treatment

Will I be paid for my time?


For more information contact:

Karely van Thiel Berghuijs


IRB#: IRB_00152764

PI: Greg Dolan


Approval Date: 2022-12-07 07:00:00

Study Categories: Cancer Studies

Specialties: Pediatric Hematology & Oncology

Last Updated: 6/8/23